New pill hopes to calm Crohn's Flare-Ups
NCT ID NCT07403968
First seen Feb 14, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study tests a new drug called zasocitinib in 20 adults with active Crohn's disease. The goal is to see if it safely reduces gut inflammation at the cellular level. Participants take the drug for 12 weeks and undergo a colonoscopy to check the bowel. This is an early-phase trial focused on safety and how the drug works, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.